Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Association between dietary zinc intake and abdominal aortic calcification in US adults.

Chen W, Eisenberg R, Mowrey WB, Wylie-Rosett J, Abramowitz MK, Bushinsky DA, Melamed ML.

Nephrol Dial Transplant. 2019 Jul 11. pii: gfz134. doi: 10.1093/ndt/gfz134. [Epub ahead of print]

PMID:
31298287
2.

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.

Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, Klaerner G, Bushinsky DA.

Lancet. 2019 Jun 24. pii: S0140-6736(19)31388-1. doi: 10.1016/S0140-6736(19)31388-1. [Epub ahead of print]

PMID:
31248662
3.

Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-Analysis.

Navaneethan SD, Shao J, Buysse J, Bushinsky DA.

Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1011-1020. doi: 10.2215/CJN.13091118. Epub 2019 Jun 13.

PMID:
31196951
4.

Diabetes Mellitus Modifies the Associations of Serum Magnesium Concentration With Arterial Calcification and Stiffness in Incident Hemodialysis Patients.

Chen W, Fitzpatrick J, Monroy-Trujillo JM, Sozio SM, Jaar BG, Estrella MM, Wu TT, Melamed ML, Parekh RS, Bushinsky DA.

Kidney Int Rep. 2019 Mar 13;4(6):806-813. doi: 10.1016/j.ekir.2019.03.003. eCollection 2019 Jun.

5.

Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats.

Krieger NS, Asplin JR, Granja I, Ramos FM, Flotteron C, Chen L, Wu TT, Grynpas MD, Bushinsky DA.

J Am Soc Nephrol. 2019 Jul;30(7):1163-1173. doi: 10.1681/ASN.2018101066. Epub 2019 May 17.

PMID:
31101664
6.

Erratum.

Bushinsky DA, Chertow GM, Cheng S, Deng H, Kopyt N, Martin KJ, Rastogi A, Ureña-Torres P, Vervloet M, Block GA.

Nephrol Dial Transplant. 2019 May 15. pii: gfz111. doi: 10.1093/ndt/gfz111. [Epub ahead of print] No abstract available.

PMID:
31093680
7.

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.

Bushinsky DA, Chertow GM, Cheng S, Deng H, Kopyt N, Martin KJ, Rastogi A, Ureña-Torres P, Vervloet M, Block GA.

Nephrol Dial Transplant. 2019 Mar 11. pii: gfz039. doi: 10.1093/ndt/gfz039. [Epub ahead of print] Erratum in: Nephrol Dial Transplant. 2019 May 15;:.

PMID:
30859218
8.

Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.

Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, Klaerner G, Bushinsky DA.

Lancet. 2019 Apr 6;393(10179):1417-1427. doi: 10.1016/S0140-6736(18)32562-5. Epub 2019 Mar 8.

PMID:
30857647
9.

Low Sodium Diet Decreases Stone Formation in Genetic Hypercalciuric Stone-Forming Rats.

Krieger NS, Grynpas M, VandenEynde A, Asplin JR, Frick KK, Kim MH, Ramos FM, Granja I, Bushinsky DA.

Nephron. 2019;142(2):147-158. doi: 10.1159/000497117. Epub 2019 Feb 6.

PMID:
30726853
10.

Tolerance to Sodium in Patients With CKD-Induced Metabolic Acidosis: Does the Accompanying Anion Matter?

Bushinsky DA.

Am J Kidney Dis. 2019 Jun;73(6):858-865. doi: 10.1053/j.ajkd.2018.09.004. Epub 2018 Dec 3.

11.

Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.

Bushinsky DA, Spiegel DM, Yuan J, Warren S, Fogli J, Pergola PE.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):103-110. doi: 10.2215/CJN.04500418. Epub 2018 Oct 31.

PMID:
30381412
12.

Patients with advanced chronic kidney disease and vascular calcification have a large hydrodynamic radius of secondary calciprotein particles.

Chen W, Anokhina V, Dieudonne G, Abramowitz MK, Kashyap R, Yan C, Wu TT, de Mesy Bentley KL, Miller BL, Bushinsky DA.

Nephrol Dial Transplant. 2019 Jun 1;34(6):992-1000. doi: 10.1093/ndt/gfy117.

13.

Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.

Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D, Zawadzki R, Berman L, Bushinsky DA.

ESC Heart Fail. 2018 Aug;5(4):592-602. doi: 10.1002/ehf2.12292. Epub 2018 May 16.

14.

Management of stones and bones: reduction of uncertainty through research.

Isakova T, Bushinsky DA.

Curr Opin Nephrol Hypertens. 2018 Jul;27(4):227-228. doi: 10.1097/MNH.0000000000000421. No abstract available.

PMID:
29702492
15.

Addressing Racial Disparity in the Progression of Chronic Kidney Disease: Prescribe More Fruits and Vegetables?

Chen W, Bushinsky DA.

Am J Nephrol. 2018;47(3):171-173. doi: 10.1159/000487716. Epub 2018 Mar 13. No abstract available.

16.

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.

Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M; Patiromer-204 Investigators.

ESC Heart Fail. 2018 Jun;5(3):257-266. doi: 10.1002/ehf2.12265. Epub 2018 Jan 25.

17.

Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.

Weir MR, Bushinsky DA, Benton WW, Woods SD, Mayo MR, Arthur SP, Pitt B, Bakris GL.

Am J Med. 2018 May;131(5):555-564.e3. doi: 10.1016/j.amjmed.2017.11.011. Epub 2017 Nov 26.

18.

Relationship of acid-base status with arterial stiffness in community-living elders: the Health ABC Study.

Chen W, Newman AB, Fried LF, Rifkin DE, Shlipak MG, Sarnak MJ, Katz R, Madero M, Raphael KL, Bushinsky DA, Ix JH.

Nephrol Dial Transplant. 2018 Sep 1;33(9):1572-1579. doi: 10.1093/ndt/gfx292.

PMID:
29177410
19.

Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.

Bushinsky DA, Hostetter T, Klaerner G, Stasiv Y, Lockey C, McNulty S, Lee A, Parsell D, Mathur V, Li E, Buysse J, Alpern R.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):26-35. doi: 10.2215/CJN.07300717. Epub 2017 Nov 4. Erratum in: Clin J Am Soc Nephrol. 2019 Jan 10;:.

20.

An in silico method to predict net calcium transfer during hemodialysis.

Maheshwari V, Cherif A, Fuertinger D, Schappacher-Tilp G, Preciado P, Thijssen S, Bushinsky DA, Kotanko P.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:2740-2743. doi: 10.1109/EMBC.2017.8037424.

PMID:
29060465
21.

Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes.

Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, Bushinsky DA.

Am J Nephrol. 2017;46(3):213-221. doi: 10.1159/000479802. Epub 2017 Sep 2.

22.

Chronic kidney disease: KDIGO CKD-MBD guideline update: evolution in the face of uncertainty.

Chen W, Bushinsky DA.

Nat Rev Nephrol. 2017 Oct;13(10):600-602. doi: 10.1038/nrneph.2017.118. Epub 2017 Aug 21. No abstract available.

PMID:
28824172
23.

Something old, something new, something borrowed, something black.

Wolf M, Bushinsky DA.

Curr Opin Nephrol Hypertens. 2017 Jul;26(4):241-242. doi: 10.1097/MNH.0000000000000325. No abstract available.

PMID:
28375872
24.

Stimulation of fibroblast growth factor 23 by metabolic acidosis requires osteoblastic intracellular calcium signaling and prostaglandin synthesis.

Krieger NS, Bushinsky DA.

Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F882-F886. doi: 10.1152/ajprenal.00522.2016. Epub 2017 Mar 15.

25.

Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM.

JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468.

26.

Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.

Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM.

JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456.

27.

Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis.

Bushinsky DA, Rossignol P, Spiegel DM, Benton WW, Yuan J, Block GA, Wilcox CS, Agarwal R.

Am J Nephrol. 2016;44(5):404-410. Epub 2016 Oct 27.

28.

Effect of Patiromer on Urinary Ion Excretion in Healthy Adults.

Bushinsky DA, Spiegel DM, Gross C, Benton WW, Fogli J, Hill Gallant KM, Du Mond C, Block GA, Weir MR, Pitt B.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1769-1776. doi: 10.2215/CJN.01170216. Epub 2016 Sep 27.

29.

Mineral metabolism: progress in the face of complexity.

Bushinsky DA, Wolf M.

Curr Opin Nephrol Hypertens. 2016 Jul;25(4):269-70. doi: 10.1097/MNH.0000000000000242. No abstract available.

PMID:
27253147
30.

Mineral metabolism: The perils of a falling PTH due to high dialysate calcium.

Chen W, Bushinsky DA.

Nat Rev Nephrol. 2016 May;12(5):264-6. doi: 10.1038/nrneph.2016.36. Epub 2016 Mar 21. No abstract available.

PMID:
26996329
31.

Increased bone density in mice lacking the proton receptor OGR1.

Krieger NS, Yao Z, Kyker-Snowman K, Kim MH, Boyce BF, Bushinsky DA.

Kidney Int. 2016 Mar;89(3):565-73. doi: 10.1016/j.kint.2015.12.020. Epub 2016 Jan 6.

32.

Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor.

Bushinsky DA, Block GA, Martin KJ, Bell G, Huang S, Sun Y, Spiegel DM, Walsh L, Mix TC, Kewalramani R.

Am J Nephrol. 2015;42(5):379-88. doi: 10.1159/000442754. Epub 2015 Dec 19.

PMID:
26684933
33.

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.

Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR.

Eur J Heart Fail. 2015 Oct;17(10):1057-65. doi: 10.1002/ejhf.402. Epub 2015 Oct 12.

34.

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.

Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, Stasiv Y, Li E, Berman L, Bakris GL.

Kidney Int. 2015 Dec;88(6):1427-1433. doi: 10.1038/ki.2015.270. Epub 2015 Sep 16.

35.

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.

Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators.

JAMA. 2015 Jul 14;314(2):151-61. doi: 10.1001/jama.2015.7446. Erratum in: JAMA. 2015 Aug 18;314(7):731. Dosage error in article text.

PMID:
26172895
36.

Modeling hypercalciuria in the genetic hypercalciuric stone-forming rat.

Frick KK, Krieger NS, Bushinsky DA.

Curr Opin Nephrol Hypertens. 2015 Jul;24(4):336-44. doi: 10.1097/MNH.0000000000000130. Review.

37.

Bones and stones, edition 2015.

Wolf M, Bushinsky DA.

Curr Opin Nephrol Hypertens. 2015 Jul;24(4):301-2. doi: 10.1097/MNH.0000000000000143. No abstract available.

PMID:
26050114
38.

Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.

Krieger NS, Asplin JR, Frick KK, Granja I, Culbertson CD, Ng A, Grynpas MD, Bushinsky DA.

J Am Soc Nephrol. 2015 Dec;26(12):3001-8. doi: 10.1681/ASN.2014121223. Epub 2015 Apr 8.

39.

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators.

N Engl J Med. 2015 Jan 15;372(3):211-21. doi: 10.1056/NEJMoa1410853. Epub 2014 Nov 21.

40.

The pursuit of truth and beauty.

Bushinsky DA, Wolf M.

Curr Opin Nephrol Hypertens. 2014 Jul;23(4):329-30. doi: 10.1097/01.mnh.0000447025.97464.ea. No abstract available.

PMID:
24840299
41.

Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Frick KK, Asplin JR, Culbertson CD, Granja I, Krieger NS, Bushinsky DA.

Am J Physiol Renal Physiol. 2014 May 1;306(9):F1081-7. doi: 10.1152/ajprenal.00680.2013. Epub 2014 Feb 26.

42.

1,25(OH)₂D₃ induces a mineralization defect and loss of bone mineral density in genetic hypercalciuric stone-forming rats.

Ng AH, Frick KK, Krieger NS, Asplin JR, Cohen-McFarlane M, Culbertson CD, Kyker-Snowman K, Grynpas MD, Bushinsky DA.

Calcif Tissue Int. 2014 May;94(5):531-43. doi: 10.1007/s00223-014-9838-7. Epub 2014 Jan 31.

43.

1,25(OH)₂D₃-enhanced hypercalciuria in genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Frick KK, Asplin JR, Krieger NS, Culbertson CD, Asplin DM, Bushinsky DA.

Am J Physiol Renal Physiol. 2013 Oct 15;305(8):F1132-8. doi: 10.1152/ajprenal.00296.2013. Epub 2013 Aug 7.

44.

Innovations in bones and stones.

Wolf M, Bushinsky DA.

Curr Opin Nephrol Hypertens. 2013 Jul;22(4):369-70. doi: 10.1097/MNH.0b013e3283622bd4. No abstract available.

PMID:
23666418
45.

Epigenetic regulation of BMP2 by 1,25-dihydroxyvitamin D3 through DNA methylation and histone modification.

Fu B, Wang H, Wang J, Barouhas I, Liu W, Shuboy A, Bushinsky DA, Zhou D, Favus MJ.

PLoS One. 2013 Apr 19;8(4):e61423. doi: 10.1371/journal.pone.0061423. Print 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/1b1eb36e-60a4-4d28-bb3a-ee5a12a3d5d8. Shuboy, Adam [added].

46.

Increased biological response to 1,25(OH)(2)D(3) in genetic hypercalciuric stone-forming rats.

Frick KK, Asplin JR, Favus MJ, Culbertson C, Krieger NS, Bushinsky DA.

Am J Physiol Renal Physiol. 2013 Mar 15;304(6):F718-26. doi: 10.1152/ajprenal.00645.2012. Epub 2013 Jan 23.

47.

The relation between bone and stone formation.

Krieger NS, Bushinsky DA.

Calcif Tissue Int. 2013 Oct;93(4):374-81. doi: 10.1007/s00223-012-9686-2. Epub 2012 Dec 18.

48.

Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone.

Krieger NS, Culbertson CD, Kyker-Snowman K, Bushinsky DA.

Am J Physiol Renal Physiol. 2012 Aug 1;303(3):F431-6. doi: 10.1152/ajprenal.00199.2012. Epub 2012 May 30.

49.

Mineral metabolism: confusion to clarity.

Bushinsky DA, Wolf MS.

Curr Opin Nephrol Hypertens. 2012 Jul;21(4):353-4. doi: 10.1097/MNH.0b013e3283546fec. No abstract available.

PMID:
22622652
50.

Sex modifies genetic effects on residual variance in urinary calcium excretion in rat (Rattus norvegicus).

Perry GM, Nehrke KW, Bushinsky DA, Reid R, Lewandowski KL, Hueber P, Scheinman SJ.

Genetics. 2012 Jul;191(3):1003-13. doi: 10.1534/genetics.112.138909. Epub 2012 May 2.

Supplemental Content

Loading ...
Support Center